Nanobiotix

Nanobiotix is a biotechnology company that uses nanomedicine to develop new radiotherapy techniques for cancer patients. The company is headquartered in Paris, with additional corporate offices in New York and Massachusetts. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo that was incorporated in 2003 and has been primarily funded by leading European venture capital firms (Matignon Technologies, OTC Asset Management, Cap Decisif, Amorcage Rhone-Alpes, CIC Vizille; Masseran Gestion-CGE). Nanobiotix, founded in 2003 based on research by Laurent Levy at SUNY Buffalo. Between 2007 and 2010, the company focused on the development of the NanoXray research program. In 2011, Nanobiotix initiated its first Phase I/II clinical study on NBTXR3 in humans, marking the commencement of treatment for the first patient in the study. The company went public in 2012, listing on the Euronext Paris market and establishing a partnership with PharmaEngine. By 2014, Nanobiotix expanded its presence to the United States with the creation of its first US subsidiary in Cambridge, Massachusetts. In 2015, the company started its first clinical trial in the United States, targeting prostate cancer with NBTXR3. In 2017, Nanobiotix opened a new facility to expand its manufacturing capabilities, increase production capacity, and prepare for commercialization.